KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Non-Current Assets (2016 - 2025)

Supernus Pharmaceuticals (SUPN) has disclosed Non-Current Assets for 15 consecutive years, with $808.5 million as the latest value for Q4 2025.

  • Quarterly Non-Current Assets rose 18.54% to $808.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.9 billion through Dec 2025, up 2.38% year-over-year, with the annual reading at $808.5 million for FY2025, 18.54% up from the prior year.
  • Non-Current Assets for Q4 2025 was $808.5 million at Supernus Pharmaceuticals, down from $825.9 million in the prior quarter.
  • The five-year high for Non-Current Assets was $1.1 billion in Q4 2021, with the low at $643.5 million in Q2 2025.
  • Average Non-Current Assets over 5 years is $858.7 million, with a median of $852.7 million recorded in 2023.
  • The sharpest move saw Non-Current Assets skyrocketed 45.61% in 2021, then fell 18.98% in 2023.
  • Over 5 years, Non-Current Assets stood at $1.1 billion in 2021, then decreased by 10.96% to $968.4 million in 2022, then decreased by 18.98% to $784.6 million in 2023, then decreased by 13.07% to $682.0 million in 2024, then rose by 18.54% to $808.5 million in 2025.
  • According to Business Quant data, Non-Current Assets over the past three periods came in at $808.5 million, $825.9 million, and $643.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.